Navigation Links
Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
Date:6/7/2012

Berlin, Germany, June 7 2012: Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation (HSCT) results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.

The ASTIS (Autologous Stem Cell Transplantation International Scleroderma) trial enrolled more than 150 patients between 2001 and 2009, and randomised patients to the HSCT arm or to intravenous pulse cyclophosphamide treatment. As of May 1, 2012, significantly more deaths have occurred in the conventional treatment group. Half of the deaths in the HSCT group occurred early and were deemed treatment-related according to an independent data monitoring committee. In the conventional treatment group in contrast, none of the deaths were deemed to be treatment-related; but more deaths occurred later and most were related to progressive disease.

"Systemic sclerosis is a debilitating disease that can lead to heart, lung or kidney failure and premature death, especially in patients who have the diffuse cutaneous form of the condition, where skin thickening is more generalised and involvement of vital organs more common. The ASTIS study shows that such patients may benefit from early intensive immunosuppressive treatment," said Professor Jaap van Laar from Newcastle University, Professor Dominique Farge, Assistance Publique Hopitaux de Paris (Sponsor in France, Paris 7 University) and Professor Alan Tyndall from Basel University, on behalf of their colleagues from the EBMT EULAR Scleroderma Study Group. "These initial results are very encouraging and will help identify patients who benefit from stem cell transplantation."

The ASTIS trial was a unique collaborative project of 27 multidisciplinary teams from 10 countries conducted
'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Fewer platelets could be used for some cancer and bone-marrow transplantation patients
2. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
3. Living donor exchange poses new option for liver transplantation
4. Cell Transplantation Eyed as Treatment for Cerebral Palsy
5. Cedars-Sinai heart transplantation tip sheet
6. Study examines global availability of treatment involving transplantation of blood stem cells
7. African-Americans and women are less likely to undergo bone marrow transplantation
8. The experience of arterial reconstruction in adult-to-adult living donor liver transplantation
9. Combination of Meniscus Allograft Transplantation and Repair of Articular Cartilage May Slow the Progression of Arthritis in the Knee
10. Stem cell transplantation of therapy-resistant chronic leukemia successful
11. New transplantation criteria for liver cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 02, 2015 , ... The 2015 China Overseas Investment and ... business conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai ... will feature leading EB-5 industry professionals and Chinese private equity partners looking for ...
(Date:9/2/2015)... ... September 02, 2015 , ... World Patent Marketing, a vertically ... safety invention that protects people from crime and other hostile situations. , "The ... CEO and Creative Director of World Patent Marketing. "The industry is growing at ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
Breaking Medicine News(10 mins):Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... The Generic Pharmaceutical Association (GPhA) will discuss the results ... healthcare market intelligence company, revealing that generic pharmaceutical utilization has ... system in the last decade., What: ... ...
... Suction Provides Permanent Reduction of Excessive Sweat and Smells , ... ... sweating and body odor affects 176 million people and in most ... breakthrough procedure, Hypo Lipo , ( Axillary Curettage Suction ) ...
... 7 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... quarter ended March 31, 2009. "Our focus for the ... the NDA submission for pixantrone while we implemented final ... needed operating capital on the least dilutive terms possible ...
... 20% to $0.49 per outstanding common share from ... in Q1 2008)- Improved average monthly revenue per ... occupancy was 88.7%, down from 90.0% in Q1 ... to $497.9 million- Improved Facility Operating Income by ...
... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...
... 125,000-member Indiana American Legion today challenged the Indiana General ... plainly on behalf of the youngsters at the Indiana ... on legislators to "not use the current budget impasse ... announced by the Indiana State Department of Health, would ...
Cached Medicine News:Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 2Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 2Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 3Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 4Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 5Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 7Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 8Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 9Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 10Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 11Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 12Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 13Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 14Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 15Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 16Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 17Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 18Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 19Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 20Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 21Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 22Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 5Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 6Health News:Legion Demands 'Courage' From Legislators in Battle Over Children's Home 2
(Date:9/2/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... for cancer, today announced results for its fiscal year ... http://photos.prnewswire.com/prnh/20140805/133834 "Despite a challenging end ... how the Company is positioned entering fiscal year 2016," ... Chief Executive Officer of MEI Pharma. "While we were ...
(Date:9/2/2015)... , Sept. 2, 2015 Delcath Systems, Inc. ... device company focused on oncology with an emphasis on ... that Company management will participate in the upcoming 17 ... from September 8-10, 2015 at the St. Regis Hotel ... MSN, CRNP, Delcath,s President and Chief Executive Officer, will ...
(Date:9/2/2015)... N.J. , Sept. 2, 2015 CytoSorbents ... leader commercializing its CytoSorb ® blood purification technology ... the world, announced that CEO Dr. Phillip Chan ... Renshaw Annual Global Investment Conference (sponsored by H.C. ... th in New York City.  ...
Breaking Medicine Technology:MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Delcath To Present At The 17th Annual Rodman & Renshaw Conference 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 2CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 4
... Inc., a preclinical stage stem cell engineering company focused on diabetes, announced ... to ViaCyte, Inc. , , ... name ViaCyte retains the Company,s identity as a leading cell therapy company, ... the Company is moving towards the market, clear and unambiguous brand recognition ...
... Children,s Hospital of Wisconsin has installed an ... hospital in the nation. Children,s Hospital, located in Milwaukee ... country. The Variety Orthopedic Center at Children,s Hospital primarily will ... and other chronic orthopedic conditions that require frequent full-spine imaging. ...
Cached Medicine Technology:Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes 2Children's Hospital of Wisconsin One of Two Pediatric Hospitals in Nation to Implement EOS Scanner 2Children's Hospital of Wisconsin One of Two Pediatric Hospitals in Nation to Implement EOS Scanner 3Children's Hospital of Wisconsin One of Two Pediatric Hospitals in Nation to Implement EOS Scanner 4
... Olympus TrueView II telescopes are based on ... unique wide field of view allows a tremendous ... view supports easy navigation in the joint with ... new quick lock mechanism for tight and secure ...
... WASCA Analyzer provides youwith new, exciting possibilities ... the WASCA Analyzeranalyzes the optical properties of ... the retina. In addition to refractive values, ... aberrations which were largely ignored in the ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
Medicine Products: